AP
IDYA icon

Antipodes Partners’s IDEAYA Biosciences IDYA Stock Holding History

Antipodes Partners’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.6K Sell
917
-233
-20% -$7.82K ﹤0.01% 113
2025
Q4 		$39.8K Buy
1,150
+380
+49% +$12.1K ﹤0.01% 111
2025
Q3 		$21K Buy
+770
New +$18.6K ﹤0.01% 111

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Antipodes Partners's IDYA Position: Q1 2026 in Review

Antipodes Partners reduced its IDEAYA Biosciences (IDYA) stake by 20% in Q1 2026, selling an estimated $7.82K and leaving 917 shares worth $30.6K. The position accounts for ﹤0.01% of the portfolio, ranked #113.

Antipodes Partners first reported a position in IDYA in Q3 2025 and has held it in 3 quarters since. The position peaked at $39.8K in Q4 2025. 253 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

  • Antipodes Partners held 917 shares of IDEAYA Biosciences worth $30.6K as of Q1 2026.
  • Antipodes Partners sold 233 IDEAYA Biosciences shares in Q1 2026, an estimated $7.82K.
  • IDEAYA Biosciences made up ﹤0.01% of Antipodes Partners's portfolio in Q1 2026, its #113 holding.
  • Antipodes Partners first reported a position in IDEAYA Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Antipodes Partners's IDEAYA Biosciences position peaked at $39.8K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.